Lupin Limited has submitted its quarterly compliance certificate to the National Stock Exchange of India Limited and BSE Limited in accordance with regulatory requirements for the quarter ended March 31, 2026.

Regulatory Compliance Submission

The pharmaceutical company filed the certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The submission was made on April 6, 2026, by Company Secretary and Compliance Officer Amit Kumar Gupta.

Certificate Details

The compliance certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. The certificate, dated April 3, 2026, was signed by Ashok Shetty, Sr. Vice President-Corporate Registry.

Confirmation of Compliance

MUFG Intime India Private Limited confirmed several key compliance aspects in their certificate:

• Securities received from depository participants for dematerialization during the quarter were properly confirmed to the depositories
• All securities comprised in the certificates have been listed on stock exchanges where previously issued securities are listed
• Security certificates received for dematerialization were confirmed or rejected within prescribed timelines
• Received certificates were mutilated and cancelled after due verification by the depository participant
• Names of depositories have been substituted in the register of members as registered owners

Corporate Information

This quarterly submission represents standard regulatory compliance for publicly listed companies to ensure transparency and proper handling of share transfer and dematerialization processes. The certificate confirms that all regulatory requirements were met during the specified quarter period.

Lupin Limited has successfully completed its strategic acquisition of VISUfarma B.V., Netherlands, through its wholly owned subsidiary Nanomi B.V. The transaction became effective on April 01, 2026, following the completion of all customary closing conditions. This acquisition significantly expands Lupin's eye care portfolio to over 60 branded products while strengthening its European market presence.

Acquisition Details and Strategic Impact

The pharmaceutical company informed stock exchanges that Nanomi B.V., its Netherlands-based wholly owned subsidiary, has acquired the entire share capital of VISUfarma B.V. from GHO Capital Partners LLP. This acquisition makes VISUfarma and its wholly owned subsidiaries part of the Nanomi group structure, bringing substantial eye care capabilities to Lupin's portfolio.

Eye Care Portfolio Expansion

The acquisition of VISUfarma represents a significant expansion of Lupin's ophthalmology segment, adding over 60 branded products to its existing eye care portfolio. The integration spans multiple therapeutic areas including dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma generated €53 million in revenue across Italy, the UK, Spain, Germany, France and certain international markets.

European Market Strengthening

VISUfarma's strong commercial footprint across key European markets is strengthened by a highly experienced team with deep ophthalmology expertise, trusted relationships, and strong local market insight. The company, founded through the combination of Italian company Visufarma SpA and European commercial activities of Nicox SA, enhances Lupin's ability to address growing global demand for innovative eye care solutions.

Management Commentary

Vinita Gupta, CEO of Lupin, stated that the VISUfarma acquisition marks a very exciting milestone for the company, adding a differentiated portfolio of more than 60 innovative eye health products supported by an established commercial infrastructure. She emphasized that beyond being immediately accretive, this strategic acquisition will expand Lupin's presence across Europe and accelerate the build-out of its specialty franchise.

Paolo Cioccetti, CEO Italy at VISUfarma, expressed enthusiasm about embarking on this next chapter with Lupin, citing their global expertise, vision, and commitment to ophthalmology as making them the ideal partner to take VISUfarma to the next level.

Corporate Structure and Compliance

With this acquisition, VISUfarma B.V. and its wholly owned subsidiaries have become wholly owned subsidiaries of Nanomi B.V., which is itself a wholly owned subsidiary of Lupin Limited. The company has fulfilled all disclosure requirements under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The completion of this acquisition represents a significant milestone in Lupin's international expansion strategy, adding VISUfarma's operations, capabilities, and extensive branded product portfolio to its global pharmaceutical business focused on improving patient health outcomes.